Treatment of Factitious Hyperthyroidism in Gestational Transient Thyrotoxicosis
Clinical Scenario
This protocol addresses factitious hyperthyroidism occurring in the setting of gestational transient thyrotoxicosis — a self-limited condition in pregnant women driven by elevated hCG levels rather than thyroid autoimmunity. It typically resolves spontaneously by the end of the first or early second trimester without lasting thyroid pathology.
Presentation Context
Gestational transient thyrotoxicosis results from the transient rise in thyroid hormones associated with high hCG levels in pregnancy, in the absence of thyroid autoimmunity. It may be complicated by hyperemesis gravidarum, which can affect the severity and the need for medical support.
Treatment Approach
Management centres on supportive measures — addressing symptoms and the clinical effects of the pregnancy-related metabolic state. Specific considerations apply regarding which pharmacological interventions are appropriate and which are not indicated in this setting.
Full regimen details, clinical decision points, and complete evidence-based guidance are available in the structured protocol below.
References
DOI: 10.1089/thy.2016.0229
Gestational transient thyrotoxicosis results from the transient increase in thyroid hormones that occur with elevated human chorionic gonadotropin (hCG) levels in pregnant women, without evidence of thyroid autoimmunity and resolves spontaneously by the end of the 1st or early 2nd trimester of pregnancy.
Manage gestational transient thyrotoxicosis through supportive therapy with anti-emetics, rehydration and hospitalization if needed, in the presence of hyperemesis gravidarum.
B-blocker can be considered, if very symptomatic.
Anti-thyroid drugs are not indicated in gestational transient thyrotoxicosis.
View source ↗